Background: u/samgold42 (24M) shared his significant weight loss journey
10.1089/ars.2012.5081 Antioxid
lower- and higher-risk), enabling to identify four risk group categories, with statistically significant different OS (p 600,000 patients
43 In a phase 3 trial including patients with obesity (excluding T2DM), the highest dose group achieved a mean weight reduction of 11.2% by week 72
To query whether weight loss by incretin agonism would impact cancer outcomes in pre-clinical models, we studied the impact of medical weight loss on two deadly cancers including pancreatic ductal adenocarcinoma (PDAC) and lung adenocarcinoma (LUAD) as either obesity-associated or obesity-independent cancers, respectively
I believe that neither of these trials took place , and the studies, as well as claimed outcomes in press releases, journals and other forms of media, are fictitious